News and Comments

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016

EXELIXIS AGAIN More...

Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Huge Improvement in the Differential Diagnosis of Diseases and More

  Wednesday, September 02, 2015

Biotechnology industry is proving to be the most innovative and the most growing among WallStreet industries. Individual biotech companies’ achievements complement each other. Some are evolving the sequencing of genes and genetic analysis, while others are excelling in designing drugs based on the tremendous amount of facts they are getting on root causes of the diseases and the interaction of proteins. The biotech companies have largely improved their drug discovery, design and development, including clinical trial plans and strategies.   More...

Seres Therapeutics: A novel Approach For Treating Clostridium Difficile infection.

  Friday, August 21, 2015

but First: Here is some Good News From  More...

SAREPTA: What's Going On ?

  Tuesday, April 16, 2013

The requests Sarepta Therapeutics (SRPT) has gotten from the FDA represent a sign of FDA seriousness towards bringing the firm’s drug eteplirsen for Duchenne muscular dystrophy as soon as possible to the children suffering from the debilitating, fast deteriorating disease. The FDA did not wait for the firm to file for early approval, it rather asked Sarepta to bring in more data that would legitimize granting early approval of the first drug ever to claim treating the disabling disease at its root-origin. Investors who should have been optimistic about the FDA initiative sold their shares instead, causing them to lose around 10% of their value.  More...

The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY

  Thursday, January 31, 2013

 More...


Recent Postings


Archive


Tags

TOKAI (TKAOI) CompuGen (CGEN) CEMPRA (CEMP) Abbott Laboratories (ABT) Theravance (THRX) AGOS (ARGS) Biogen Idec (BIIB) Array Pharmaceuticals (ARRY) RenenxBio (RGNX) ZALTRAP™ PTC Therapeutics (PTCT) NANTKWEST (NK) ACADIA (ACAD) Anadys (ANDS) Merck (MRK) Roche (ROCHE) Agenus (AGEN) Advaxis (ADXS) Rapamune Bristol-Myers Squibb (BMY) OSI (OSIP) Revlimid (lenolidamide) Alder Biopharmaceuticals (ALDR) INNOVIVA (INVA) Gilead (GILD) C4 Therapeutics Biocryst (BCRX) HALOZYME (HALO) Multiple Myeloma Illumina (ILMN) Exelixis (EXEL) Ridaforolimus Sanofi-Aventis (SAN) Agenus (AGEN Sangamo (SGMO) Zerenex Herceptin Theravance Bio Pharma (TBPH) Telaprevir Pluristem (PSTI) Vertex (VRTX) Spike Therapeutics (ONCE) Galena (GALE) Dendreon (DNDN) Elan (ELN) Bellicum (BLCM) Inovio (INO) MODERNA Ariad (ARIA) SUNESIS PHARMACEUTICALS (SNSS) Prolor Biotech (PBTH) Anacor (ANAC) galapagos (GLPG) KITE (KITE) Onyx (ONXX) Aimmune Therapeutics (AIMT) Adaptimmune (ADAP) NOVOCURE (NVCR) Seattle Genetics (SGEN) SERES THERAPEUTICS (MCRB) Human Genome Sciences (HGSI) PORTOLA (PTLA) Tysabri Intrexon (XON) VANDA (VNDA) KERYX (KERX) Trastuzumab-DM1 NEKTAR (NKTR)) Dynavax (DVAX) Valeant Pharmaceuticals International (VRX) Idenix (IDIX) Mirati Therapeutics (MRTX) Velcade (bortezomib) Amgen (AMGN) JUNO (JUNO) Sequenom (SQNM) Sanofi (SNY) GlaxoSmithKline (GSK) ABBVIE (ABBV) Incyte (INCY) Cytokinetics (CYTK) ARCA (ABIO) Prosensa (RNA) Global Cell Therapeutics (GBT) Genentech ImmunoGen (IMGN) Benlysta (belimumab) Intermune (ITMN) Ionis (IONS) Sanofi (SNA) Intercept (ICPT) Human Longevity (HLI) Micromet (MITI) Auspex (ASPX) ARGOS (ARGS) Editas (EDIT) Endometrial Cancer Vitae Pharmaceuticals (VTAE) AERIE PHARMACEUTICALS GUARDIAN HEALTH Jazz Pharmaceuticals (JAZZ) IDERA (IDRA) Alnylam (ALNY) Ziofpharm (ZIOP) CRISPR Therapeutics (CRSP) REGULUS (RGLS) Sarepta (SRPT) Xoma (XOMA) AstraZeneca (AZN) SYNTA (SNTA) ISIS (ISIS) Roche (RHHBY) ADVENTRIX (ANX) Ocular Therapeutix (OCUL) Regeneron (REGN) BIOMARIN (BMRN)